Clinical trials: Kidney Failure
Beta-thalassemia, Myelodysplastic Syndromes
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
The purpose of this study is to determine the effects of the oral iron chelator Deferasirox on liver iron content after one year of treatment in patients with iron overload from repeated blood transfusions.
- Conditions
- Beta-thalassemia, Myelodysplastic Syndromes, Fanconi Syndrome, Anemia, Diamond-Blackfan
- Trial name
- NCT00061763
- Testing
- Deferasirox
- Where
- 6 sites in United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria.
- Trial name
- MIRO-CKD (NCT06350123)
- Where
- 92 sites in United States, Austria and 13 more
- Volunteers
- 324 people
- Sponsor
- AstraZeneca
Renal Insufficiency, Acute, Renal Insufficiency, Chronic
Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency
This is a Phase 1, open-label, single-dose study of the safety, tolerability, and pharmacokinetics of Minocin® (minocycline) for injection in subjects with renal insufficiency.
- Conditions
- Renal Insufficiency, Acute, Renal Insufficiency, Chronic, Healthy Subjects
- Trial name
- NCT02808052
- Testing
- Minocin (minocycline) for Injection
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
End Stage Renal Disease
Comparison of Daily Home Hemodialysis (HD) With Conventional in Center HD in Terms of Patients Quality of Life and Clinical Outcomes
The objective of this study is to describe the characteristics of patients on daily home hemodialysis and to confirm in real practice in France the effectiveness shown in studies, mainly American, both in terms of clinical…
- Trial name
- SeCoIA (NCT03737578)
- Testing
- Delivery of a connected pedometer / accelerometer
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Physidia
Diabetic Nephropathy, Type 2 Diabetes
Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy
The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.
- Trial name
- NCT01843387
- Testing
- Mesenchymal Precursor Cells (MPCs)
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Mesoblast, Ltd.
Chronic Renal Failure
Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers
This study is a randomized, open-label, single dosing, 3-treatment, 6-sequence, 3-period, crossover-design study to compare the pharmacokinetics and safety of D113 with CKD-349 in healthy volunteers.
- Trial name
- NCT04952506
- Testing
- CKD-349 F1 Tab., CKD-349 F2 Tab., D113 Tab.
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Atrial Fibrillation, Renal Dysfunction
A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban
This study aims to evaluate the recommended once-daily dosing of edoxaban and rivaroxaban in patients with atrial fibrillation (AF) and renal dysfunction in South Korea and Taiwan.
- Trial name
- NCT07874555
- Testing
- Edoxaban, Rivaroxaban
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 8,265 people
- Sponsor
- Daiichi Sankyo
Chronic Kidney Disease, Arterial Hypertension
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
In this study, researchers want to learn about the safety of BAY3283142 after a single dose and multiple doses in participants with mild to moderate high blood pressure.
- Trial name
- NCT06428825
- Testing
- BAY3283142
- Where
- 2 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Secondary Hyperparathyroidism, Chronic Kidney Disease
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.
- Trial name
- NCT02341417
- Testing
- Cinacalcet
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 28 people
- Sponsor
- Amgen
Renal Impairment, Healthy
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
- Conditions
- Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
- Trial name
- NCT07165015
- Testing
- LY3537031
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Kidney Diseases, Pruritus
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in…
- Trial name
- NCT05356403
- Testing
- Difelikefalin 1 mg Oral Tablet
- Where
- 75 sites in United States, Argentina and 11 more
- Volunteers
- 105 people
- Sponsor
- Cara Therapeutics, Inc.
Hyperuricemia, Gout
An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in subjects with hyperuricemia in an inpatient, controlled setting.
- Conditions
- Hyperuricemia, Gout, Chronic Kidney Diseases
- Trial name
- NCT04987242
- Testing
- ALLN-346
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Allena Pharmaceuticals
Chronic Renal Failure
Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic renal failure. 120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl). Renamezin is administered 6.0mg/day.
- Trial name
- NCT02681991
- Testing
- Renamezin capsule
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Vascular Access, End Stage Renal Disease
A Multi Center, Study to Evaluate the Safety and Efficacy of the VasQ External Support Device for Arteriovenous Fistulas
This study is a prospective, multi center, randomized, controlled study of the VasQ in arteriovenous fistulas. The VasQ constraints and directs the geometrical parameters of the fistula as well as the vascular diameter and…
- Trial name
- NCT02112669
- Testing
- VasQ
- Where
- 4 sites in Israel, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Laminate Medical Technologies
Renal Impairment
Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment
To investigate the pharmacokinetics (PK) of POL7080 in subjects with renal function impairment after single intravenous (IV) infusion of POL7080
- Trial name
- NCT02110459
- Testing
- POL7080
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Polyphor Ltd.
Acute Kidney Injury
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
This study will assess the safety and efficacy of BCT197 on acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.
- Trial name
- NCT01336959
- Testing
- BCT197 Part A, BCT197 Part B
- Where
- 13 sites in United States, Israel and 1 more
- Volunteers
- 91 people
- Sponsor
- Mereo BioPharma
Renal Insufficiency, Kidney Diseases
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
- Trial name
- NCT05624723
- Testing
- INCB054707
- Where
- 2 sites in United States, Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Hyperphosphatemia, End-Stage Renal Disease
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs.
- Trial name
- NCT01074125
- Testing
- ferric citrate
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 154 people
- Sponsor
- Keryx Biopharmaceuticals
Nephrotic Syndrome
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
- Trial name
- NCT05599815
- Testing
- ADX-629
- Where
- 11 sites in United States
- Sponsor
- Aldeyra Therapeutics, Inc.
Hepatorenal Syndrome, Acute Kidney Injury
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
- Trial name
- NCT05875948
- Testing
- R2R01, Terlipressin
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- River 2 Renal Corp.